News and Comments

Onyx (ONXX) Was Right All Along

  Monday, July 26, 2010

In October 2009, Onyx (ONXX) paid $276 million up front to acquire the privately held Proteolix to get to its multiple myeloma drug carfilzomib. It promised $535 million in future payments largely contingent on carfilzomib's approval. As usual, investors did not like Onyx paying money, because investors do not like any company to pay money to develop or acquire state-of-the- art products. When somebody hates something he sees everything in it with pessimism. Onyx put its hands on carfilzomib, which looked very promising for multiple myeloma cases resistant to current treatments. The breakthrough multiple myeloma drugs Velcade (bortezomib) and Revlimid (lenolidamide) could not prevent the cancer from recurring and failed to work at all on a large percentage of recurrent cancer.  More...


Recent Postings


Archive


Tags

Ariad (ARIA) ADVENTRIX (ANX) REGULUS (RGLS) ARGOS (ARGS) Benlysta (belimumab) Advaxis (ADXS) Illumina (ILMN) Global Cell Therapeutics (GBT) Incyte (INCY) Idenix (IDIX) Merck (MRK) Multiple Myeloma Gilead (GILD) Jazz Pharmaceuticals (JAZZ) ISIS (ISIS) Amgen (AMGN) MODERNA Intrexon (XON) Anacor (ANAC) Editas (EDIT) Inovio (INO) galapagos (GLPG) VANDA (VNDA) NANTKWEST (NK) Theravance (THRX) Sarepta (SRPT) Biocryst (BCRX) CEMPRA (CEMP) Micromet (MITI) OSI (OSIP) Valeant Pharmaceuticals International (VRX) Sanofi (SNA) Biogen Idec (BIIB) Aimmune Therapeutics (AIMT) Velcade (bortezomib) SERES THERAPEUTICS (MCRB) Pluristem (PSTI) SUNESIS PHARMACEUTICALS (SNSS) Xoma (XOMA) Elan (ELN) ARCA (ABIO) Intermune (ITMN) Agenus (AGEN Alder Biopharmaceuticals (ALDR) Intercept (ICPT) Cytokinetics (CYTK) GUARDIAN HEALTH ABBVIE (ABBV) Tysabri Telaprevir Sanofi (SNY) JUNO (JUNO) Dynavax (DVAX) Ionis (IONS) Auspex (ASPX) Human Genome Sciences (HGSI) Genentech IDERA (IDRA) Roche (ROCHE) AERIE PHARMACEUTICALS AGOS (ARGS) Galena (GALE) Exelixis (EXEL) Spike Therapeutics (ONCE) Agenus (AGEN) Human Longevity (HLI) Zerenex Onyx (ONXX) PTC Therapeutics (PTCT) BIOMARIN (BMRN) Mirati Therapeutics (MRTX) NOVOCURE (NVCR) Roche (RHHBY) ImmunoGen (IMGN) SYNTA (SNTA) KERYX (KERX) Trastuzumab-DM1 CRISPR Therapeutics (CRSP) Revlimid (lenolidamide) PORTOLA (PTLA) KITE (KITE) ZALTRAP™ Anadys (ANDS) Dendreon (DNDN) Seattle Genetics (SGEN) Vertex (VRTX) Bellicum (BLCM) GlaxoSmithKline (GSK) Theravance Bio Pharma (TBPH) INNOVIVA (INVA) Ridaforolimus ACADIA (ACAD) NEKTAR (NKTR)) Sangamo (SGMO) HALOZYME (HALO) Prosensa (RNA) Adaptimmune (ADAP) JOUNCE THERAPEUTICS (JNCE) Sanofi-Aventis (SAN) CompuGen (CGEN) Ocular Therapeutix (OCUL) Bristol-Myers Squibb (BMY) AstraZeneca (AZN) Ziofpharm (ZIOP) Herceptin Rapamune TOKAI (TKAOI) C4 Therapeutics Abbott Laboratories (ABT) Regeneron (REGN) Vitae Pharmaceuticals (VTAE) Sequenom (SQNM) Endometrial Cancer Array Pharmaceuticals (ARRY) RenenxBio (RGNX) Alnylam (ALNY) Prolor Biotech (PBTH)